Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Jean Trebek, Lisa Swayze, Joan Vassos, Stephen Nichols, Jeff Mauro, Jonathan Frakes, Kitty Swink, Rosa Blasi and Many More Raise [...] READ MORE ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results